| Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (NCT05257408) | Corcept Therapeutics | 2022-06-29 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (NCT05194072) | Seagen, a wholly owned subsidiary of Pfizer | 2022-01-12 |
| Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). (NCT05116189) | Merck Sharp & Dohme LLC | 2021-12-13 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer (NCT04807166) | Wenjun Cheng | 2021-08-24 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (NCT04556071) | Xiaoxiang Chen | 2020-11-06 |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (NCT04111978) | Swiss GO Trial Group | 2020-11-05 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (NCT04498117) | CanariaBio Inc. | 2020-08-25 |
| Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer (NCT04794322) | Massachusetts General Hospital | 2020-04-13 |
| An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT01932125) | Hoffmann-La Roche | 2018-12-05 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (NCT03648489) | Imperial College London | 2018-09-21 |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (NCT03593681) | Boston Scientific Corporation | 2018-08-27 |
| Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers (NCT03976999) | Institut du Cancer de Montpellier - Val d'Aurelle | 2017-07-05 |
| Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (NCT02903771) | Kazia Therapeutics Limited | 2016-12-05 |
| HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life (NCT03000192) | University Hospital Southampton NHS Foundation Trust | 2016-08-01 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (NCT02658214) | AstraZeneca | 2016-04-28 |
| Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy (NCT02786524) | University of Michigan | 2016-02-15 |
| DNA Single Nucleotide Polymorphisms as Predictors of Toxicity (NCT02478476) | OvaGene Oncology, Inc. | 2015-07-01 |
| A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT01846611) | Janssen Research & Development, LLC | 2013-10-16 |
| 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant (NCT01766622) | National Institutes of Health Clinical Center (CC) | 2012-11-30 |
| Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer (NCT01681368) | National Cancer Institute (NCI) | 2012-08-15 |
| A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors (NCT01478685) | Celgene | 2011-11-29 |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (NCT01462890) | AGO Study Group | 2011-11-01 |
| Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer (NCT01279291) | Kyowa Kirin Co., Ltd. | 2011-01-01 |
| Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT01131039) | Emory University | 2011-01-01 |
| A Prospective Trial of COXEN Chemotherapy Prediction (NCT01228942) | University of Virginia | 2010-10-01 |
| Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer (NCT01313078) | National Cancer Institute (NCI) | 2010-01-01 |
| A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers (NCT00698451) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2008-08-01 |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00445549) | National Cancer Institute (NCI) | 2007-01-01 |
| Pharmacogenomics of Paclitaxel in Ovarian Cancer (NCT00415207) | University of Southern Denmark | 2006-12-01 |
| ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma (NCT00407407) | Celgene | 2006-11-01 |
| Pharmacogenomics of Paclitaxel in Ovarian Cancer (NCT00415181) | University of Southern Denmark | 2006-09-01 |
| Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas (NCT00443196) | Pierian Biosciences | 2006-03-01 |
| Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients (NCT00189345) | AGO Study Group | 2004-05-01 |
| Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer (NCT00074867) | Pfizer | 2003-10-01 |
| Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response (NCT00103545) | AGO Study Group | 2003-07-01 |
| An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy (NCT00191646) | Eli Lilly and Company | 2002-10-01 |
| A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. (NCT00191607) | Eli Lilly and Company | 2002-07-01 |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer (NCT00035100) | Novartis Pharmaceuticals | 2001-09-01 |